#HVO hVIVO PLC – MSD to acquire Cidara November 27, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, congratulates its client Cidara Therapeutics, Inc (“Cidara” or the “partner”) which has entered into a definitive agreement under which Merck Sharp & Dohme LLC (“MSD”), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO’s unique capabilities in accelerating drug development and validates the…

#HVO hVIVO PLC – Positive results from flu human challenge study April 3, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Cidara Therapeutics, Inc. (“Cidara”), reporting positive interim results from an ongoing human challenge study testing CD388. hVIVO is conducting the Phase 2a single-center, randomised, double-blinded, placebo-controlled trial using its H3N2 Influenza Human Challenge Study Model. CD388 is…

#HVO hVIVO PLC – MSD to acquire Cidara November 27, 2025 – Posted in: hVIVO (HVO)

#HVO hVIVO PLC – Positive results from flu human challenge study April 3, 2023 – Posted in: hVIVO (HVO)

Address

Contact

Social

LEGAL